Tag Archives: NICE
Biotech drugs: Pushing policy boundaries
Since the passage of the Medicare prescription drug benefit (Part D), Medicare policy and pricing decisions have taken on a role normally assigned to the market: the ongoing challenge to balance access considerations, the role and strength of evidence for efficacy and safety, and the cost of new treatments. Biotech medicines are under the spotlight for a number of reasons. Continue reading
